Drug Trial Radar · NCT07838194
Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Sep 30, 2028
Study completion Sep 30, 2031
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Chugai Pharmaceutical
- First posted
- Sep 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis in pediatric patients aged 0 to 11 years with severe or moderate congenital hemophilia A without factor VIII inhibitors or congenital hemophilia A of any severity (severe, moderate, and mild) with inhibitors (emicizumab-naïve and treated). Patients with hemophilia A aged ≥12 to \<18 years old with a body weight of \<40 kilograms (kg) are also able to participate.
Conditions
- Hemophilia A
Interventions
NXT007Drug
NXT007 will be administered subcutaneously (SC) according to the schedule in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Bleed Rate (ABR) for Treated Bleeds Over the Main Study Treatment PeriodTime frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St. Marianna University Hospital
Kawasaki-Shi, Kanagawa, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.